Holen Sie sich die Stockscreener-App
185.67
0.18%
0.34
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$185.33
Offen:
$185.99
24-Stunden-Volumen:
1.50M
Relative Volume:
0.78
Marktkapitalisierung:
$287.95B
Einnahmen:
$60.48B
Nettoeinkommen (Verlust:
$10.40B
KGV:
55.76
EPS:
3.3297
Netto-Cashflow:
$8.05B
1W Leistung:
-0.73%
1M Leistung:
+0.25%
6M Leistung:
+100.25%
1J Leistung:
+161.99%
1-Tages-Spanne:
$184.65
$187.10
1-Wochen-Bereich:
$183.35
$188.72
52-Wochen-Spanne:
$68.61
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Compare AZN vs LLY, JNJ, ABBV, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
185.67 | 287.42B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,105.00 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
225.33 | 555.59B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
217.72 | 386.27B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
118.72 | 296.11B | 65.51B | 8.93B | 14.12B | 3.5532 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-27 | Eingeleitet | Citigroup | Buy |
| 2025-10-27 | Fortgesetzt | Jefferies | Buy |
| 2025-10-16 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2025-02-13 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-20 | Hochstufung | UBS | Sell → Neutral |
| 2024-11-06 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-16 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Sell |
| 2024-01-03 | Herabstufung | Jefferies | Buy → Hold |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-25 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-12 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-05 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-09-15 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Hochstufung | Argus | Hold → Buy |
| 2022-06-14 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-11 | Hochstufung | DZ Bank | Sell → Hold |
| 2021-12-07 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-12 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-12 | Herabstufung | Argus | Buy → Hold |
| 2021-03-16 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Hochstufung | UBS | Neutral → Buy |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-12-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Hochstufung | UBS | Sell → Neutral |
| 2020-11-11 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2019-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-10-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-02 | Herabstufung | UBS | Neutral → Sell |
| 2019-02-05 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2019-01-25 | Hochstufung | Shore Capital | Hold → Buy |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-08-16 | Herabstufung | Jefferies | Buy → Hold |
| 2018-03-19 | Hochstufung | Jefferies | Hold → Buy |
| 2018-02-06 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-05 | Bestätigt | Bernstein | Outperform |
| 2018-01-18 | Bestätigt | Leerink Partners | Mkt Perform |
| 2017-12-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Hochstufung | Bernstein | Mkt Perform → Outperform |
Alle ansehen
Astrazeneca Plc Aktie (AZN) Neueste Nachrichten
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million - The Motley Fool
AstraZeneca gets FDA nod for new hypertension drug Baxfendy - MSN
AstraZeneca targets year end for COVID-19 vaccine - Edition.mv
AstraZeneca plc stock (GB0009895292): CARES phase 3 data spotlight subgroup benefit after missed end - AD HOC NEWS
AstraZeneca PLC stock (US6549022043): FDA approval for Imfinzi in early bladder cancer adds to US on - AD HOC NEWS
AstraZeneca plc stock (GB0009895292): London-listed pharma group in focus after new CelLBxHealth par - AD HOC NEWS
ASCO26: AstraZeneca’s light chain amyloidosis shows subgroup benefit after Phase III trial - Clinical Trials Arena
CSPC Pharmaceutical receives $1.2 billion upfront payment from AstraZeneca - marketscreener.com
US bank sees positive risk-reward for AstraZeneca ahead of pivotal heart drug trial - Proactive financial news
AstraZeneca highlights data insights from Cares clinical programme - London South East
WINNERS & LOSERS: CelLBxHealth jumps on AstraZeneca partnership - marketscreener.com
CelLBxHealth shares jump on partnership with AstraZeneca - London South East
AstraZeneca's Imfinzi Gets US FDA Nod for Bladder Cancer Combo Therapy - Yahoo Finance UK
CelLBxHealth secures AstraZeneca agreement to provide circulating tumour cell analytics services (CLBX) - Yahoo Finance UK
CelLBxHealth rises 33% after signing AstraZeneca deal - Share Talk
Astrazeneca Obtains US Approval for Imfinzi-based Bladder Cancer Combination Therapy - marketscreener.com
CelLBxHealth shares jump 36% after master services agreement with AstraZeneca - Proactive financial news
Astrazeneca's Imfinzi receives green light from US FDA - Sharecast.com
CelLBxHealth PLC Enters Master Services Agreement With AstraZeneca PLC - marketscreener.com
AstraZeneca’s Imfinzi Plus BCG Approved By FDA For High-risk Bladder Cancer - DirectorsTalk Interviews
CellBxHealth enters master services agreement with AstraZeneca - marketscreener.com
AstraZeneca says Imfinzi approved in US for early bladder cancer - marketscreener.com
AstraZeneca (AZN) withdraws listing for 1.200% Notes due 2026 from NYSE - Stock Titan
AstraZeneca's Durvalumab Approved by FDA in Combination With BCG for Bladder Cancer - marketscreener.com
FDA oncology roundup: AbbVie’s rare cancer approval, AstraZeneca in breast cancer limbo - Pharmaceutical Technology
AstraZeneca PLC stock (US6549022043): FDA extends review for key breast cancer drug as London shares - AD HOC NEWS
ASTRAZENECA : Deutsche Bank keeps a Sell rating - marketscreener.com
PLATINUM INVESTMENT MANAGEMENT LTD's AstraZeneca PLC(AZN) Holding History - GuruFocus
AZN Stock Quote Price and Forecast - CNN
Why Are AstraZeneca, GSK and Hikma Lifting FTSE 100 Focus? - Kalkine Media
Expert View: Greencore, Autotrader, Watkin Jones, and Astrazeneca - Citywire
AstraZeneca PLC stock (US6549022043): FDA extends camizestrant review as investors weigh oncology mo - AD HOC NEWS
AstraZeneca plc stock (GB0009895292): FDA extends camizestrant review - AD HOC NEWS
FDA delays decision on AstraZeneca breast cancer pill - BioPharma Dive
AstraZeneca says FDA has delayed review of breast cancer therapy camizestrant - Seeking Alpha
FDA Delays AstraZeneca's Breast Cancer Drug Review: What to Know - PharmTech.com
AstraZeneca PLC stock (US6549022043): oncology pipeline, Obesity franchise and US market focus in th - AD HOC NEWS
FDA extends review period for AstraZeneca’s camizestrant breast cancer application - Investing.com India
AstraZeneca (AZN) sees FDA delay but EMA backs camizestrant combo - Stock Titan
Why Are AstraZeneca HSBC And Diageo Trending - Kalkine Media
AstraZeneca PLC ADR Dividends – BCBA:AZN.CI - TradingView
US FDA pushes back decision on Astrazeneca's camizestrant - Sharecast.com
US regulator delays decision on AstraZeneca cancer drug - Financial Times
AstraZeneca says FDA extends breast cancer drug review period - London South East
US FDA extends review of AstraZeneca’s experimental breast cancer pill - Reuters
FTSE 100: AstraZeneca (LSE:AZN) Faces Fresh Market Spotlight - Kalkine Media
US FDA decision date extended for SERENA-6 filing of camizestrant to enable review of additional data - AstraZeneca
AstraZeneca Unit Keeps Cancer Therapy IP Despite Stada Jab - Law360
Astrazeneca Pharma India March-quarter PAT 448.8 million rupees - marketscreener.com
AstraZeneca breast cancer drug camizestrant recommended for EU approval - Investing.com
Datroway extends survival in TNBC as AstraZeneca (NYSE: AZN) gains US ok - Stock Titan
Finanzdaten der Astrazeneca Plc-Aktie (AZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.81%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):